Prevalence of diabetes and impaired glucose regulation in Estonia

Eglit, Triin; Rajasalu, Tarvo; Lember, Margus

doi:10.1111/j.1464-5491.2010.03218.x

Cited by 5 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recent studies from Europe that have estimated prevalence according to NCEP ATP III in age groups comparable to that of our study population have shown comparable results: 25.9% in Norway [18], 28.8% in Turkey [19], and 24.7% in Luxembourg [20]. Furthermore, our estimates of the prevalence of diabetes (7.0%) and impaired glucose tolerance (8.0%) in Estonia are also in comparable to those of other developed countries [16]. Thus, the prevalence of metabolic disorders in Estonia—a former socialist country undergoing a rapid transition to the Western sedentary lifestyle—appears to be similar to the rest of the developed world.…”

Section: Discussionsupporting

confidence: 85%

“…Prevalence was significantly ( P -value = 0.02) higher in men when compared to women in the youngest age-group only, and there were no gender-specific differences in prevalence in the middle and older age-groups (Table 1). Prevalence data on diabetes, impaired glucose tolerance, and impaired fasting glucose in our study population has been published elsewhere [16]. Most of the subjects with MS had 3 components of the syndrome (56.4%), 31.5% had 4, and 12.1% had all 5 components.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic Syndrome in Estonia: Prevalence and Associations with Insulin Resistance

Eglit

Rajasalu

Lember

2012

International Journal of Endocrinology

View full text Add to dashboard Cite

Recently, it has been suggested that metabolic syndrome should be considered a premorbid condition in younger individuals. We evaluated the prevalence of metabolic syndrome in Estonia and compared the characteristic profiles between morbid metabolic syndrome (previously established diabetes, hypertension, or dyslipidaemia) and premorbid metabolic syndrome subgroups. Our study was a cross-sectional, population-based sample of the general population in Estonia aged 20–74 years (n = 495). Metabolic syndrome was diagnosed by National Cholesterol Education Program Adult Treatment Panel III criteria. Insulin resistance was estimated using the homeostasis model assessment (HOMA-IR). The crude and weighted prevalence of metabolic syndrome was 27.9% and 25.9%, respectively. Despite being significantly younger, the premorbid subgroup showed similar levels of insulin resistance as the morbid subgroup (mean HOMA-IR ± SD 2.73 ± 1.8 versus 2.97 ± 2.1, P = 0.5). The most important attribute of metabolic syndrome is insulin resistance, which already characterises metabolic syndrome in the early stages of its metabolic abnormalities.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Resultsmentioning

confidence: 99%

Metabolic Syndrome in Estonia: Prevalence and Associations with Insulin Resistance

Eglit

Rajasalu

Lember

2012

International Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…The global prevalence of diabetes of nearly 10% is still increasing [35,36] and provokes major cardiovascular morbidity and mortality. If Zn supplementation were added as an official recommendation, it would potentially affect more than 500 million people [35].…”

Section: Introductionmentioning

confidence: 99%

Raised dietary Zn:Cu ratio increases the risk of atherosclerosis in type 2 diabetes

Kärberg

Forbes

Lember

2022

Clinical Nutrition ESPEN

View full text Add to dashboard Cite

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia

Malkin¹,

Russel-Szymczyk²,

Liidemann³

et al. 2018

Diabetes Ther

View full text Add to dashboard Cite

IntroductionOnce-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 analogue liraglutide in a recent network meta-analysis (NMA). The aim of the present study was to assess the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.2 mg in Estonia.MethodsOutcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model (version 9.0), with baseline cohort characteristics sourced from SUSTAIN 3 and changes in HbA1c, systolic blood pressure (SBP), and BMI associated with once-weekly semaglutide and liraglutide derived from the NMA. Patients were assumed to receive once-weekly semaglutide or liraglutide for 5 years before intensifying to basal insulin. Treatment effects were applied for the first 5 years, after which HbA1c increased to 7.0%, SBP followed a natural progression, and BMI reverted to baseline for the remainder of the analysis. Costs were expressed in euros (EUR) and estimated from a healthcare payer perspective. Utilities associated with diabetes and diabetes-related complications were taken from published sources.ResultsOnce-weekly semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.13 quality-adjusted life years (QALYs) versus liraglutide 1.2 mg. Direct costs were EUR 67 higher with once-weekly semaglutide, due to the increased acquisition cost, but this was mostly offset by cost savings due to avoidance of diabetes-related complications. Once-weekly semaglutide 1 mg was therefore associated with an incremental cost-effectiveness ratio of EUR 523 per QALY gained versus liraglutide 1.2 mg, which falls well below a willingness-to-pay threshold of EUR 52,390 per QALY gained (three times the Estonian GDP per capita).ConclusionOnce-weekly semaglutide was considered highly cost-effective versus liraglutide 1.2 mg for the treatment of patients with type 2 diabetes in Estonia.FundingNovo Nordisk A/S.Plain Language SummaryPlain language summary available for this article.

show abstract

Prevalence of diabetes and impaired glucose regulation in Estonia

Cited by 5 publications

References 2 publications

Metabolic Syndrome in Estonia: Prevalence and Associations with Insulin Resistance

Metabolic Syndrome in Estonia: Prevalence and Associations with Insulin Resistance

Raised dietary Zn:Cu ratio increases the risk of atherosclerosis in type 2 diabetes

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia

Contact Info

Product

Resources

About